MX2017016331A - Sales de ácido graso de glicopirronio y métodos para elaborar las mismas. - Google Patents

Sales de ácido graso de glicopirronio y métodos para elaborar las mismas.

Info

Publication number
MX2017016331A
MX2017016331A MX2017016331A MX2017016331A MX2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A
Authority
MX
Mexico
Prior art keywords
fatty acid
glycopyrronium
acid salts
methods
reaction mixture
Prior art date
Application number
MX2017016331A
Other languages
English (en)
Inventor
Itute MOBELE Bingidimi
Karl Liu Xuejun
Goud Puppali Satish
Eisenreich Emerich
A Rich Steven
Original Assignee
Qaam Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qaam Pharmaceuticals Llc filed Critical Qaam Pharmaceuticals Llc
Publication of MX2017016331A publication Critical patent/MX2017016331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
    • G01N2030/8854—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds involving hydrocarbons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8868—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample elemental analysis, e.g. isotope dilution analysis

Abstract

Se han desarrollado nuevas sales de ácido graso de glicopirronio. Las condiciones de reacción bi-fásicas permiten las reacciones de intercambio de contraión deseadas entre bromuro de glicopirronio y sales de ácido graso de metales alcalinos y metales alcalinotérreos en métodos para formar sales de ácido graso de glicopirronio. En modalidades preferidas, un exceso del ácido graso libre en la mezcla de reacción estabiliza la sal de ácido graso de glicopirronio y reduce la formación de la impureza, Ácido A. En algunas modalidades preferidas, entre 0.2 y 1.2 equivalentes molares de ácido graso libre en exceso se adiciona a la mezcla de reacción. En otra modalidad, aproximadamente 1.2 equivalentes molares de ácido graso libre en exceso se adiciona a la mezcla de reacción.
MX2017016331A 2015-06-15 2016-06-06 Sales de ácido graso de glicopirronio y métodos para elaborar las mismas. MX2017016331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175737P 2015-06-15 2015-06-15
PCT/US2016/035967 WO2016204998A1 (en) 2015-06-15 2016-06-06 Glycopyrronium fatty acid salts and methods of making same

Publications (1)

Publication Number Publication Date
MX2017016331A true MX2017016331A (es) 2018-09-05

Family

ID=57546015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016331A MX2017016331A (es) 2015-06-15 2016-06-06 Sales de ácido graso de glicopirronio y métodos para elaborar las mismas.

Country Status (11)

Country Link
US (1) US10519109B2 (es)
EP (1) EP3307250B1 (es)
JP (1) JP6910069B2 (es)
KR (1) KR20180037947A (es)
CN (1) CN108024967B (es)
AU (1) AU2016279798B2 (es)
CA (1) CA2989579A1 (es)
ES (1) ES2942176T3 (es)
MA (1) MA43047A (es)
MX (1) MX2017016331A (es)
WO (1) WO2016204998A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954191B2 (en) * 2017-03-12 2021-03-23 Sol-Gel Technologies Ltd. Process for the preparation of glycopyrrolate tosylate
CN109884205A (zh) * 2019-03-12 2019-06-14 康诚科瑞医药研发（武汉）有限公司 一种血浆中曲司氯铵的定量检测方法
KR20200129895A (ko) 2019-05-10 2020-11-18 오남주 스마트 태양광 파고라
TW202245748A (zh) 2021-02-05 2022-12-01 日商三和化學研究所股份有限公司 包含吡咯醣･水楊酸鹽之藥品
CA3206833A1 (en) 2021-02-05 2022-08-11 Sanwa Kagaku Kenkyusho Co., Ltd. Medicine comprising glycopyrronium salicylate

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892944A (en) 1987-05-13 1990-01-09 Mitsubishi Petrochemical Co., Ltd. Process for producing quaternary salts
EP0412798A3 (en) 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US6063808A (en) 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
KR20000022239A (ko) 1996-07-11 2000-04-25 토마스 헤인 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체
CN1183124C (zh) * 1999-10-15 2005-01-05 丹尼斯科卡尔特美国公司 山梨醇与脂肪酸的直接酯化法
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP2283818B1 (en) * 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
JP2004083456A (ja) * 2002-08-26 2004-03-18 Fuji Photo Film Co Ltd ジアゾニウム塩の製造方法
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2005003108A1 (ja) * 2003-07-01 2005-01-13 Otsuka Chemical Co., Ltd. 第４級アンモニウム塩および電解質並びに電気化学デバイス
US7091236B1 (en) 2003-08-20 2006-08-15 Sciele Pharma, Inc. Method for increasing the bioavailability of glycopyrrolate
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
ATE520390T1 (de) * 2004-12-27 2011-09-15 Beiersdorf Ag Glycopyrrolat in kosmetischen zubereitungen
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
JP2007090557A (ja) * 2005-09-27 2007-04-12 Fujifilm Corp 光学フィルムの製造方法、光学フィルム並びに画像表示装置
KR20090054434A (ko) * 2006-07-28 2009-05-29 바이오그레이드 (홍콩) 피티와이 리미티드 마스터배치 및 폴리머 조성물
WO2008019070A2 (en) * 2006-08-04 2008-02-14 Ebrahim Versi Pharmaceutical compositions of trospium for treating smooth muscle hyperactivity disorders
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US9034890B2 (en) 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
WO2009052353A2 (en) * 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP2271218B1 (en) 2008-03-27 2017-05-24 Chase Pharmaceuticals Corporation Use and composition for treating dementia
JP4621783B2 (ja) * 2008-03-31 2011-01-26 株式会社日本触媒 フルオロスルホニルイミド類およびその製造方法
WO2009153886A1 (ja) * 2008-06-20 2009-12-23 旭化成ケミカルズ株式会社 α－ヒドロキシ酸の製造方法
KR101955863B1 (ko) * 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
CN101935286A (zh) * 2009-06-26 2011-01-05 出光兴产株式会社 具有金刚烷基的季铵盐的制备方法
MX345236B (es) 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
CN102939281A (zh) 2010-06-14 2013-02-20 奇斯药制品公司 格隆氯铵的制备方法
ES2702487T3 (es) 2011-06-17 2019-03-01 Nantenergy Inc Líquido iónico que contiene iones sulfonato
JP5885459B2 (ja) * 2011-10-21 2016-03-15 Ｋｊケミカルズ株式会社 非水溶性イオン性ビニルモノマーの製造方法及びそれからなる帯電防止剤と帯電防止組成物
JP2013227247A (ja) * 2012-04-25 2013-11-07 Kohjin Holdings Co Ltd 非水溶性イオン性ビニルモノマーの製造方法及びそれからなる帯電防止剤と帯電防止組成物
WO2014091384A2 (en) 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis

Also Published As

Publication number Publication date
MA43047A (fr) 2018-08-08
EP3307250A4 (en) 2018-08-08
CN108024967B (zh) 2021-12-21
US10519109B2 (en) 2019-12-31
EP3307250B1 (en) 2022-11-23
ES2942176T3 (es) 2023-05-30
US20180179156A1 (en) 2018-06-28
EP3307250A1 (en) 2018-04-18
AU2016279798A1 (en) 2018-01-18
WO2016204998A1 (en) 2016-12-22
CA2989579A1 (en) 2016-12-22
JP6910069B2 (ja) 2021-07-28
KR20180037947A (ko) 2018-04-13
AU2016279798B2 (en) 2021-07-08
JP2018519289A (ja) 2018-07-19
CN108024967A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2017016331A (es) Sales de ácido graso de glicopirronio y métodos para elaborar las mismas.
PH12019501857A1 (en) High density aqueous well fluids
MX2016012764A (es) Produccion de una sal de hexafluorofosfato y de pentafluoruro de fosforo.
MX2013011259A (es) Proceso de aminacion reductora para la preparacion de la dronedarona usando el compuesto intermediario de amina.
IN2014CN04224A (es)
MX2023005704A (es) Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo.
SG10201806830RA (en) Preparation of N,N-(di)alkylaminoalkyl(meth)acrylamide or N,N-(di)alkylaminoalkyl (meth)acrylate and the quaternary ammonium salts thereof as flocculating aids and gelling agents
IN2015DN01519A (es)
RU2013122694A (ru) Способ получения сульфата-нитрата аммония
MX2020000886A (es) Inhibidores de ror gamma.
MX2022009281A (es) Inhibidores de rorgamma.
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
AR071060A1 (es) Proceso para la preparacion de betainas
MX2018007982A (es) Proceso para la preparacion de 1,1,3-trioxo-1,2-benzotiazol-6-carb oxamida.
PH12016500913A1 (en) Soap bar
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
MX2020005335A (es) Fertilizantes novedosos fosfaticos basados en sakes de alcanolamina de acido fosforico.
PH12018500677A1 (en) Method for producing optically active 2- (2-fluorobiphenyl-4-yl) propanoic acid
IN2014DN06539A (es)
MX2020006837A (es) Metodo para producir un compuesto de sal de tiocarboxamidina.
PH12014501704A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
IN2014DN10324A (es)
PL420099A1 (pl) Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych
EA201790367A1 (ru) Водные скважинные флюиды высокой плотности